Plain-English translation of NCT07535463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called , combined with standard chemotherapy and a type of targeted radiation called stereotactic radiosurgery, to treat non-small cell lung cancer that has spread to the brain. The trial will first figure out the safest dose of the medication to use alongside chemotherapy and radiation. Once the right dose is found, researchers will test whether this combination actually works to shrink or control brain tumors.
Brain metastases (cancer that has spread to the brain) are very serious and difficult to treat. Doctors want to see if adding this new immunotherapy medication to chemotherapy and radiation therapy can help patients with this condition better than current treatments alone.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication as an infusion on your first day of treatment, along with chemotherapy. A few days later (around days 7–10), you will begin stereotactic radiosurgery, which delivers focused radiation beams to your brain tumors over three sessions. After a checkup about three weeks in, you will continue receiving the medication and standard chemotherapy doses as your doctor decides. The study has two phases: the first determines the safest dose, and the second tests whether that dose works well in a new group of patients.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States